Who makes 300IU rec-LH?

300IU rec-LH is developed by Universitair Ziekenhuis Brussel.

What development phase is 300IU rec-LH in?

300IU rec-LH is FDA-approved (marketed).

Last reviewed 2026-05-15 · How we verify

300IU rec-LH

Universitair Ziekenhuis Brussel · FDA-approved active Small molecule Quality 1/100

At a glance

Generic name	300IU rec-LH
Sponsor	Universitair Ziekenhuis Brussel
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Luteal Supplementation With Rec-LH After GnRH-agonist Triggering in In Vitro (IVF) (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

300IU rec-LH CI brief — competitive landscape report
300IU rec-LH updates RSS · CI watch RSS
Universitair Ziekenhuis Brussel portfolio CI